Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center

Prostate Cancer and Prostatic Diseases volume 16, pages 85–90 (2013)Cite this article

Subjects

Abstract

Background:

Active surveillance (AS) is increasingly utilized in low-risk prostate cancer (PC) patients. Although black race has traditionally been associated with adverse PC characteristics, its prognostic value for patients managed with AS is unclear.

Methods:

A retrospective review identified 145 patients managed with AS at the Duke Prostate Center from January 2005 to September 2011. Race was patient-reported and categorized as black, white or other. Inclusion criteria included PSA <10 ng ml−1, Gleason sum ⩽6, and ⩽33% of cores with cancer on diagnostic biopsy. The primary outcome was discontinuation of AS for treatment due to PC progression. In men who proceeded to treatment after AS, the trigger for treatment, follow-up PSA and biopsy characteristics were analyzed. Time to treatment was analyzed with univariable and multivariable Cox proportional hazards models and also stratified by race.

Results:

In our AS cohort, 105 (72%) were white, 32 (22%) black and 8 (6%) another race. Median follow-up was 23.0 months, during which 23% percent of men proceeded to treatment. The demographic, clinical and follow-up characteristics did not differ by race. There was a trend toward more uninsured black men (15.6% black, 3.8% white, 0% other, P=0.06). Black race was associated with treatment (hazard ratio (HR) 2.93, P=0.01) as compared with white. When the analysis was adjusted for socioeconomic and clinical parameters at the time of PC diagnosis, black race remained the sole predictor of treatment (HR 3.08, P=0.01). Among men undergoing treatment, the trigger was less often patient driven in black men (8 black, 33 white, 67% other, P=0.05).

Conclusions:

Black race was associated with discontinuation of AS for treatment. This relationship persisted when adjusted for socioeconomic and clinical parameters.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664–2670.

    Article  Google Scholar 

  2. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A . Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126–131.

    Article  Google Scholar 

  3. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185–2190.

    Article  Google Scholar 

  4. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181: 1635–1641.

    Article  Google Scholar 

  5. Johansson J-E, Andrén O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–2719.

    Article  CAS  Google Scholar 

  6. Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.

    Article  Google Scholar 

  7. Freedland SJ, Isaacs WB . Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005; 62: 243–252.

    Article  Google Scholar 

  8. Barocas DA, Penson DF . Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int 2010; 106: 322–328.

    Article  Google Scholar 

  9. Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 2006; 176: 515–519.

    Article  Google Scholar 

  10. Jani AB, Gratzle J . Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings. Urology 2005; 66: 124–129.

    Article  Google Scholar 

  11. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM et al. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 2004; 96: 939–944.

    PubMed  PubMed Central  Google Scholar 

  12. Barrett WL, Kassing WM, Shirazi R . Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians. Brachytherapy 2004; 3: 30–33.

    Article  Google Scholar 

  13. Resnick MJ, Canter DJ, Guzzo TJ, Brucker BM, Bergey M, Sonnad SS et al. Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy? Urology 2009; 73: 620–623.

    Article  CAS  Google Scholar 

  14. Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD . Do African American men have lower survival from prostate cancer compared with white men? A meta-analysis. Am J Mens Health 2010; 4: 189–206.

    Article  Google Scholar 

  15. Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL et al. Race, biochemical disease recurrence, and prostate–specific antigen doubling time after radical prostatectomy. Cancer 2007; 110: 2202–2209.

    Article  CAS  Google Scholar 

  16. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, DuChane J, Carroll PR et al. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer. Cancer 2006; 106: 789–795.

    Article  Google Scholar 

  17. Winkfield KM, Chen M-H, Dosoretz DE, Salenius SA, Katin M, Ross R et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Rad Oncol Biol Phy 2011; 81: e345–e350.

    Article  Google Scholar 

  18. Yamoah K, Stone N, Stock R . Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 2011; 117: 5589–5600.

    Article  Google Scholar 

  19. Tarman GJ, Kane CJ, Moul JW, Thrasher JB, Foley JP, Wilhite D et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology 2000; 56: 1016–1020.

    Article  CAS  Google Scholar 

  20. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439–445.

    Article  Google Scholar 

  21. Johnstone PAS, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the department of defense center for prostate disease research1. Radiology 2002; 225: 420–426.

    Article  Google Scholar 

  22. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA . Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol 2010; 28 (6): 1069–1074.

    Article  Google Scholar 

  23. Schwartz K, Powell IJ, Underwood Iii W, George J, Yee C, Banerjee M . Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009; 74: 1296–1302.

    Article  Google Scholar 

  24. Tewari AK, Gold HT, Demers RY, Johnson CC, Yadav R, Wagner EH et al. Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer. Urology 2009; 73: 624–630.

    Article  Google Scholar 

  25. Chu DI, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK et al. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2012; e-pub ahead of print, 13 March 2012.

  26. Banez LL, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL et al. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 2009; 18: 1208–1212.

    Article  Google Scholar 

  27. Cullen J, Brassell SA, Chen Y, Porter C, L’Esperance J, Brand T et al. Racial/ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer 2011; 2011: 234519.

    Article  Google Scholar 

  28. Koscuiszka M, Hatcher D, Christos PJ, Rose AE, Greenwald HS, Chiu Y-l et al. Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. Cancer 2011; 118: 3145–3152.

    Article  Google Scholar 

  29. Iremashvili V, Soloway MS, Rosenberg DL, Manoharan M . Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 2012; 187: 1594–1600.

    Article  Google Scholar 

  30. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF . Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044–1051.

    Article  Google Scholar 

  31. Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis W, Moul J et al. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care 2004; 42: 239–250.

    Article  Google Scholar 

  32. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274: 1277–1281.

    Article  CAS  Google Scholar 

  33. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W . Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white american men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792–1797.

    Article  Google Scholar 

  34. Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004; 171 (Pt 1): 2277–2280.

    Article  CAS  Google Scholar 

  35. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang B-D et al. Identification of differentially methylated genes in normal prostate tissues from african american and caucasian men. Clin Cancer Res 2010; 16: 3539–3547.

    Article  CAS  Google Scholar 

  36. Kim HS, Moreira DM, Jayachandran J, Gerber L, Banez LL, Vollmer RT et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis 2011; 14: 262–265.

    Article  CAS  Google Scholar 

  37. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 29: 2795–2800.

    Article  Google Scholar 

Download references

Acknowledgements

This work was financially supported by Duke Urology Committee for Urologic Research, Education and Development (CURED) Endowment Fund.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery and the Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

    M R Abern, M R Bassett, M Tsivian, L L Bañez, T J Polascik, M N Ferrandino, C N Robertson, S J Freedland & J W Moul

Authors
  1. M R Abern
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M R Bassett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Tsivian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L L Bañez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T J Polascik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M N Ferrandino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C N Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S J Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J W Moul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J W Moul.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abern, M., Bassett, M., Tsivian, M. et al. Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center. Prostate Cancer Prostatic Dis 16, 85–90 (2013). https://doi.org/10.1038/pcan.2012.38

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.38

Keywords

This article is cited by

Search

Advanced search

Quick links